Repligen (RGEN)
Repligen on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
7.6M
Short interest
settlement 2026-09-30
6.6
Days to cover
-0.5 days vs prior
72.8%
Short share of volume
2026-10-09
321
Fails to deliver
settlement 2026-09-11
Tue 27 Oct
Next earnings
estimated date
-$6.0M
Insider flow, 90 days
0 buys, 8 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in RGEN is 7,581,634 shares, up 968,757 shares over the last month. Over the last 48 readings it ranged from 3,169,466 shares (31 December 2024) to 7,581,634 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 1.1M shares a day that is 6.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/rgen" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 7,581,634 | +12.9% | 1,146,770 | 6.61 |
| 2026-09-15 | 6,712,693 | +1.5% | 947,188 | 7.09 |
| 2026-08-31 | 6,612,877 | +8.7% | 990,264 | 6.68 |
| 2026-08-14 | 6,085,313 | -0.8% | 944,670 | 6.44 |
| 2026-07-31 | 6,132,499 | +5.5% | 1,561,230 | 3.93 |
| 2026-07-15 | 5,811,745 | -3.9% | 732,447 | 7.93 |
| 2026-06-30 | 6,048,812 | +5.6% | 1,299,524 | 4.65 |
| 2026-06-15 | 5,726,265 | -4.0% | 900,271 | 6.36 |
| 2026-05-29 | 5,962,038 | +4.7% | 1,218,461 | 4.89 |
| 2026-05-15 | 5,695,614 | +3.5% | 1,471,558 | 3.87 |
| 2026-04-30 | 5,501,852 | +0.3% | 1,105,002 | 4.98 |
| 2026-04-15 | 5,486,281 | -1.3% | 781,416 | 7.02 |
| 2026-03-31 | 5,556,333 | +28.0% | 887,353 | 6.26 |
| 2026-03-13 | 4,340,746 | +8.4% | 930,189 | 4.67 |
| 2026-02-27 | 4,003,984 | -1.1% | 792,897 | 5.05 |
| 2026-02-13 | 4,048,179 | -0.2% | 838,751 | 4.83 |
| 2026-01-30 | 4,054,509 | +3.3% | 598,529 | 6.77 |
| 2026-01-15 | 3,923,966 | -0.2% | 692,097 | 5.67 |
| 2025-12-31 | 3,933,025 | -4.5% | 518,171 | 7.59 |
| 2025-12-15 | 4,120,083 | -4.4% | 664,064 | 6.20 |
| 2025-11-28 | 4,309,467 | +5.5% | 681,820 | 6.32 |
| 2025-11-14 | 4,085,106 | +23.0% | 897,923 | 4.55 |
| 2025-10-31 | 3,320,400 | -1.8% | 1,239,729 | 2.68 |
| 2025-10-15 | 3,382,265 | -0.9% | 1,049,495 | 3.22 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of RGEN volume is 72.8%, down 7.7 points over the last five sessions. Over the last 30 readings it ranged from 43.8% (8 October 2026) to 88.5% (18 September 2026). The latest reading is 6.8 points above the 30-session average of 66.0%, on 664K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 483K | 664K | 72.8% | 9 |
| 2026-10-08 | 225K | 513K | 43.8% | 19,007 |
| 2026-10-07 | 356K | 529K | 67.2% | 36 |
| 2026-10-06 | 427K | 703K | 60.7% | 4,999 |
| 2026-10-05 | 333K | 465K | 71.7% | 4,400 |
| 2026-10-02 | 572K | 711K | 80.5% | 21 |
| 2026-10-01 | 619K | 991K | 62.5% | 111,266 |
| 2026-09-30 | 237K | 296K | 80.1% | 15,500 |
| 2026-09-29 | 393K | 587K | 66.9% | 87 |
| 2026-09-28 | 420K | 611K | 68.8% | 0 |
| 2026-09-25 | 362K | 492K | 73.6% | 64 |
| 2026-09-24 | 552K | 822K | 67.2% | 2 |
| 2026-09-23 | 209K | 384K | 54.4% | 85 |
| 2026-09-22 | 472K | 565K | 83.5% | 274 |
| 2026-09-21 | 260K | 322K | 80.7% | 301 |
| 2026-09-18 | 285K | 322K | 88.5% | 24 |
| 2026-09-17 | 386K | 563K | 68.6% | 6 |
| 2026-09-16 | 238K | 373K | 63.9% | 0 |
| 2026-09-15 | 310K | 420K | 73.8% | 452 |
| 2026-09-14 | 148K | 256K | 57.7% | 4 |
| 2026-09-11 | 239K | 272K | 87.8% | 295 |
| 2026-09-10 | 307K | 481K | 63.8% | 633 |
| 2026-09-09 | 263K | 480K | 54.7% | 6,900 |
| 2026-09-08 | 207K | 336K | 61.6% | 271 |
| 2026-09-04 | 193K | 353K | 54.5% | 270 |
| 2026-09-03 | 251K | 551K | 45.6% | 82 |
| 2026-09-02 | 216K | 429K | 50.4% | 100 |
| 2026-09-01 | 285K | 635K | 44.9% | 165 |
| 2026-08-31 | 199K | 328K | 60.8% | 0 |
| 2026-08-28 | 238K | 349K | 68.2% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 11 September 2026, the fails-to-deliver balance in RGEN is 321 shares, up 319 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (9 September 2026) to 72,778 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-11 | 321 | $164.68 | $53K |
| 2026-09-09 | 2 | $168.53 | $337 |
| 2026-09-04 | 9 | $169.61 | $2K |
| 2026-09-01 | 61 | $180.98 | $11K |
| 2026-08-25 | 1,553 | $181.62 | $282K |
| 2026-08-24 | 16,628 | $181.13 | $3.0M |
| 2026-08-21 | 4,812 | $180.29 | $868K |
| 2026-08-19 | 33 | $166.15 | $5K |
| 2026-08-17 | 492 | $166.83 | $82K |
| 2026-08-13 | 52 | $165.70 | $9K |
| 2026-08-10 | 15 | $163.90 | $2K |
| 2026-08-07 | 234 | $159.44 | $37K |
| 2026-08-04 | 6,257 | $147.06 | $920K |
| 2026-08-03 | 1,376 | $141.01 | $194K |
| 2026-07-30 | 29 | $141.23 | $4K |
| 2026-07-28 | 6,541 | $131.06 | $857K |
| 2026-07-24 | 200 | $137.60 | $28K |
| 2026-07-23 | 200 | $140.09 | $28K |
| 2026-07-22 | 216 | $136.99 | $30K |
| 2026-07-14 | 458 | $144.88 | $66K |
| 2026-07-13 | 3 | $144.24 | $433 |
| 2026-07-09 | 86 | $137.41 | $12K |
| 2026-07-06 | 5,315 | $142.40 | $757K |
| 2026-07-02 | 890 | $138.99 | $124K |
| 2026-06-30 | 72,778 | $137.00 | $10.0M |
| 2026-06-29 | 11 | $147.01 | $2K |
| 2026-06-22 | 466 | $132.02 | $62K |
| 2026-06-18 | 39,045 | $133.55 | $5.2M |
| 2026-06-16 | 483 | $130.87 | $63K |
| 2026-06-08 | 500 | $122.31 | $61K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at RGEN reported 8 open-market sells worth $6.0M in the last 90 days and no open-market buys. Latest filing: Douglass Brian Robb (CHIEF PRODUCT OFFICER) on 2026-10-06.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Douglass Brian Robb | CHIEF PRODUCT OFFICER | Grant | 700 | $0.00 | $0 | 9K |
| 2026-10-05 | Loeillot Olivier | Chief Executive Officer | Sell | 4K | $190.00 | $798K | 46K |
| 2026-10-05 | Loeillot Olivier | Chief Executive Officer | Option exercise | 4K | $154.96 | $651K | 50K |
| 2026-10-05 | Loeillot Olivier | Chief Executive Officer | Sell | 1K | $178.75 | $238K | 46K |
| 2026-10-02 | Loeillot Olivier | Chief Executive Officer | Tax withholding | 1K | $181.70 | $227K | 47K |
| 2026-09-25 | Garland Jason K | CFO | Tax withholding | 421 | $189.68 | $80K | 18K |
| 2026-09-24 | Loeillot Olivier | Chief Executive Officer | Sell | 5K | $190.00 | $863K | 48K |
| 2026-09-24 | Loeillot Olivier | Chief Executive Officer | Option exercise | 5K | $155.38 | $706K | 53K |
| 2026-09-24 | Loeillot Olivier | Chief Executive Officer | Sell | 8K | $190.00 | $1.6M | 48K |
| 2026-09-24 | Loeillot Olivier | Chief Executive Officer | Option exercise | 8K | $154.96 | $1.3M | 57K |
| 2026-09-21 | Loeillot Olivier | Chief Executive Officer | Sell | 5K | $180.00 | $977K | 48K |
| 2026-09-21 | Loeillot Olivier | Chief Executive Officer | Option exercise | 5K | $141.79 | $769K | 54K |
| 2026-09-04 | Loeillot Olivier | Chief Executive Officer | Sell | 3K | $165.90 | $504K | 48K |
| 2026-09-03 | Loeillot Olivier | Chief Executive Officer | Tax withholding | 3K | $169.61 | $482K | 51K |
| 2026-09-01 | Hughes Violetta | CHIEF ACCOUNTING OFFICER | Tax withholding | 277 | $170.02 | $47K | 6K |
| 2026-08-20 | Loeillot Olivier | Chief Executive Officer | Sell | 5K | $180.00 | $977K | 54K |
| 2026-08-20 | Loeillot Olivier | Chief Executive Officer | Option exercise | 5K | $141.79 | $769K | 60K |
| 2026-07-16 | Garland Jason K | CFO | Sell | 530 | $150.00 | $80K | 19K |
| 2026-06-25 | Garland Jason K | CFO | Sell | 733 | $145.00 | $106K | 19K |
| 2026-05-14 | Pax Margaret | Director | Grant | 995 | $0.00 | $0 | 3K |
| 2026-05-14 | Mhatre Rohin | Director | Grant | 995 | $0.00 | $0 | 5K |
| 2026-05-14 | Madaus Martin D | Director | Grant | 995 | $0.00 | $0 | 7K |
| 2026-05-14 | MUIR GLENN P | Director | Grant | 995 | $0.00 | $0 | 40K |
| 2026-05-14 | Konstantinov Konstantin | Director | Grant | 995 | $0.00 | $0 | 4K |
| 2026-05-14 | EGLINTON MANNER CARRIE | Director | Grant | 995 | $0.00 | $0 | 5K |
| 2026-05-14 | DAWES KAREN A | Director | Grant | 995 | $0.00 | $0 | 93K |
| 2026-05-14 | BARTHELEMY NICOLAS | Director | Grant | 995 | $0.00 | $0 | 5K |
| 2026-05-07 | MUIR GLENN P | Director | Option exercise | 2K | $38.76 | $94K | 39K |
| 2026-05-07 | Douglass Brian Robb | CHIEF PRODUCT OFFICER | Tax withholding | 334 | $126.43 | $42K | 8K |
| 2026-04-21 | Loeillot Olivier | Chief Executive Officer | Sell | 4K | $140.00 | $536K | 54K |
| 2026-03-05 | Hughes Violetta | CHIEF ACCOUNTING OFFICER | Grant | 2K | $0.00 | $0 | 7K |
| 2026-03-05 | Loeillot Olivier | Chief Executive Officer | Grant | 24K | $0.00 | $0 | 58K |
| 2026-03-05 | KURIYEL RALF | Senior VP, R&D | Grant | 5K | $0.00 | $0 | 20K |
| 2026-03-05 | Garland Jason K | CFO | Grant | 8K | $0.00 | $0 | 20K |
| 2026-03-05 | Bylund James | Chief Operating Officer | Grant | 8K | $0.00 | $0 | 25K |
| 2026-03-04 | KURIYEL RALF | Senior VP, R&D | Tax withholding | 42 | $125.84 | $5K | 15K |
| 2026-03-04 | KURIYEL RALF | Senior VP, R&D | Grant | 125 | $0.00 | $0 | 15K |
| 2026-03-04 | Bylund James | Chief Operating Officer | Tax withholding | 62 | $125.84 | $8K | 18K |
| 2026-03-04 | Bylund James | Chief Operating Officer | Grant | 125 | $0.00 | $0 | 18K |
| 2026-03-02 | Loeillot Olivier | Chief Executive Officer | Tax withholding | 2K | $124.97 | $201K | 34K |
| 2026-03-02 | KURIYEL RALF | Senior VP, R&D | Tax withholding | 923 | $124.97 | $115K | 15K |
| 2026-03-02 | Hunt Anthony | Director | Tax withholding | 10K | $124.97 | $1.2M | 89K |
| 2026-03-02 | Garland Jason K | CFO | Tax withholding | 715 | $124.97 | $89K | 12K |
| 2026-03-02 | Douglass Brian Robb | CHIEF PRODUCT OFFICER | Tax withholding | 221 | $124.97 | $28K | 8K |
| 2026-03-02 | Bylund James | Chief Operating Officer | Tax withholding | 2K | $124.97 | $304K | 18K |
| 2026-02-27 | Loeillot Olivier | Chief Executive Officer | Tax withholding | 344 | $128.73 | $44K | 36K |
| 2026-02-27 | KURIYEL RALF | Senior VP, R&D | Tax withholding | 444 | $128.73 | $57K | 16K |
| 2026-02-27 | Garland Jason K | CFO | Tax withholding | 327 | $128.73 | $42K | 13K |
| 2026-02-27 | Bylund James | Chief Operating Officer | Tax withholding | 1K | $128.73 | $190K | 20K |
| 2025-12-31 | Douglass Brian Robb | CHIEF PRODUCT OFFICER | Grant | 2K | $0.00 | $0 | 9K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON14 Form 144 notices on file for RGEN worth $15.3M at the prices reported; 7 in the last 90 days worth $6.0M. Latest: Loeillot Olivier filed on 2026-10-05 to sell 4,202 shares ($798K) from 2026-10-05.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-05 | Loeillot OlivierOfficer, Director | 4K | $798K | 0.007% | 2026-10-05 | Fidelity Brokerage Services LLC |
| 2026-10-05 | Loeillot OlivierOfficer, Director | 1K | $238K | 0.002% | 2026-10-05 | Fidelity Brokerage Services LLC |
| 2026-09-24 | Loeillot OlivierOfficer, Director | 13K | $2.5M | 0.023% | 2026-09-24 | Fidelity Brokerage Services LLC |
| 2026-09-21 | Loeillot OlivierOfficer, Director | 5K | $977K | 0.010% | 2026-09-21 | Fidelity Brokerage Services LLC |
| 2026-09-04 | Loeillot OlivierOfficer, Director | 3K | $504K | 0.005% | 2026-09-04 | Fidelity Brokerage Services LLC |
| 2026-08-20 | Loeillot OlivierOfficer, Director | 5K | $977K | 0.010% | 2026-08-20 | Fidelity Brokerage Services LLC |
| 2026-07-16 | Garland Jason KOfficer | 530 | $80K | 0.001% | 2026-07-16 | Fidelity Brokerage Services LLC |
| 2026-06-25 | Garland Jason KOfficer | 733 | $106K | 0.001% | 2026-06-25 | Fidelity Brokerage Services LLC |
| 2026-04-21 | Loeillot OlivierOfficer, Director | 4K | $536K | 0.007% | 2026-04-21 | Fidelity Brokerage Services LLC |
| 2025-12-17 | DAWES KAREN ADirector | 275 | $44K | 0.000% | 2025-12-17 | Fidelity Brokerage Services LLC |
| 2025-11-25 | Loeillot OlivierOfficer, Director | 7K | $1.2M | 0.013% | 2025-11-25 | Fidelity Brokerage Services LLC |
| 2025-11-18 | Bylund JamesOfficer | 2K | $331K | 0.004% | 2025-11-18 | Fidelity Brokerage Services LLC |
| 2025-11-13 | Hunt AnthonyDirector | 20K | $3.1M | 0.036% | 2025-11-13 | Fidelity Brokerage Services LLC |
| 2025-11-12 | Hunt AnthonyDirector | 25K | $3.9M | 0.044% | 2025-11-12 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of RGEN in their latest filing, all on Schedule 13G (passive). The largest reported stake is Abigail P. Johnson at 13.0% of the class (7,361,318 shares), filed 2026-10-07 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-07 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 7.4M | 13.0% | 2026-09-30 |
| 2026-10-07 | 13G/Ano. 1 | FMR LLCparent holding company | 7.4M | 13.0% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 8 | T. Rowe Price Associates, Inc.investment adviser | 1.8M | 3.1% | 2026-06-30 |
| 2026-07-31 | 13G | Vanguard Capital Managementinvestment adviser | 2.8M | 5.0% | 2026-06-30 |
| 2026-03-27 | 13G/Ano. 7 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-13 | 13G/Ano. 8 | Roy T. Eddleman Living Trustother entity | 2.7M | 4.8% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 8 | Roy T. Eddleman Charitable Remainder Trust #1other entity | 30K | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 8 | Roy T. Eddleman Charitable Remainder Trust #2other entity | 0 | 0.0% | 2025-12-31 |
13F holders
Tracked managers holding RGEN at their latest 13F. JSON6 of the 30 tracked managers held RGEN at their latest 13F, $98.5M in total at quarter-end prices. Citadel Advisors is the largest at $51.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 376K | $51.3M | 0.01% | -723K |
| Point72 Asset Management | 2026-06-30 | 166K | $22.7M | 0.03% | -403K |
| D. E. Shaw & Co. | 2026-06-30 | 83K | $11.4M | 0.01% | new |
| Duquesne Family Office | 2026-06-30 | 77K | $10.6M | 0.20% | new |
| Two Sigma Investments | 2026-06-30 | 10K | $1.4M | 0.00% | new |
| AQR Capital Management | 2026-06-30 | 9K | $1.2M | 0.00% | +56 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated $117.4M of operating cash flow. As of 2026-06-30, cash was $606.8M against $551.0M of debt.
- Cash
- $606.8M
- Debt
- $551.0M
- Equity
- $2.11B
- Total assets
- $2.95B
- Shares outstanding
- 56,435,621
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | $5.0M | n/a | 0.09 |
| Q1 FY 2026 | 2026-03-31 | n/a | $8.3M | n/a | 0.15 |
| Q4 FY 2025derived | 2025-12-31 | n/a | $13.3M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | $14.9M | n/a | 0.26 |
| Q2 FY 2025 | 2025-06-30 | n/a | $14.9M | n/a | 0.26 |
| Q1 FY 2025 | 2025-03-31 | n/a | $5.8M | n/a | 0.10 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$33.9M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$654K | n/a | -0.01 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | $48.9M | $117.4M | $23.5M | $0 | n/a |
| FY 2024 | 2024-12-31 | n/a | -$25.5M | $175.4M | $25.7M | $0 | n/a |
| FY 2023 | 2023-12-31 | n/a | $35.6M | $113.9M | $36.2M | $14.4M | n/a |
| FY 2022 | 2022-12-31 | n/a | $186.0M | $172.1M | $84.8M | $0 | n/a |
| FY 2021 | 2021-12-31 | n/a | $128.3M | $119.0M | $67.1M | $0 | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-24 from the cover page.
What this page is
Repligen in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Repligen (RGEN), SEC CIK 730272, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-11.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-05.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-28.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-06.JSON and CSV
- Company record
- EDGAR filing index for CIK 730272Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- MRNAModerna
- TWSTTwist Bioscience
- ADPTAdaptive Biotechnologies
- NVAXNovavax
- RXRXRecursion Pharmaceuticals
- DNAGinkgo Bioworks Holdings
- PCVXVaxcyte
- NBIXNeurocrine Biosciences
- VIRVir Biotechnology
- EXELExelixis
- RVMDRevolution Medicines
- GILDGilead Sciences
- HALOHalozyme Therapeutics
- KYMRKymera Therapeutics
- AMGNAmgen
- KRYSKrystal Biotech
- VCELVericel
- BIIBBiogen
- CRSPCRISPR Therapeutics
- DNLIDenali Therapeutics
- KODKodiak Sciences
- BDTXBlack Diamond Therapeutics
- TECHBio-Techne
- BEAMBeam Therapeutics
Datasets
Frequently Asked Questions
How much of RGEN is sold short?
What is RGEN's daily short volume?
Does RGEN have fails to deliver?
Are RGEN insiders buying or selling?
Have RGEN insiders filed to sell?
Who owns 5% or more of RGEN?
What did RGEN report last quarter?
Which tracked 13F managers own RGEN?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.